EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

New coumarin–chalcone–triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validation

Fariba Peytam, Maryam Norouzbahari, Mahsa Akbari, Hayrettin Ozan Gülcan, Mahfam Moradi, Somayeh Mojtabavi iD, Mohammad Ali Faramarzi iD, Fahimeh Ghasemi, Mohammadreza Torabi, Maliheh Barazandeh Tehrani, Vahid Sheibani, Loghman Firoozpour und 1 weitere

RSC Advances · 2025 · 15 (59) · 51136-51161

DOI: 10.1039/d5ra07254a ↗

Kurz gefasst

Fachartikel in der Zeitschrift RSC Advances, 2025. Verfasst von Fariba Peytam und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences Tehran Iran. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Tehran University of Medical Sciences and Health Services.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel coumarin–chalcone–triazole hybrids were designed and synthesized as potent α-glucosidase inhibitors. Lead compound 20q showed exceptional enzymatic potency, strong selectivity, and remarkable in vivo antihyperglycemic activity.

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences Tehran Iran.
  • Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences Tehran Iran.
  • Faculty of Pharmacy, Final International University Kyrenia via Mersin 10 Turkey TRNC Catalkoy Turkey.
  • Eastern Mediterranean University, Faculty of Pharmacy TRNC, via Mersin 10 Turkey Famagusta Cyprus.
  • Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences Tehran Iran.
  • Department of Bioinformatics and Systems Biology, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences Isfahan Iran.

ORCID-Profile: Somayeh Mojtabavi, Mohammad Ali Faramarzi, Alireza Foroumadi

Förderung

  • Tehran University of Medical Sciences and Health Services

Zitieren

APA

Peytam, F., Norouzbahari, M., Akbari, M., Gülcan, H. O., Moradi, M., Mojtabavi, S., Faramarzi, M. A., Ghasemi, F., Torabi, M., Tehrani, M. B., Sheibani, V., Firoozpour, L., & Foroumadi, A. (2025). New coumarin–chalcone–triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validation. RSC Advances, 15(59), 51136-51161. https://doi.org/10.1039/d5ra07254a

Vancouver

Peytam F, Norouzbahari M, Akbari M, Gülcan HO, Moradi M, Mojtabavi S, et al. New coumarin–chalcone–triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validation. RSC Advances. 2025;15(59):51136-51161. doi:10.1039/d5ra07254a

BibTeX
@article{Peytam2025,
  author = {Peytam, Fariba and Norouzbahari, Maryam and Akbari, Mahsa and Gülcan, Hayrettin Ozan and Moradi, Mahfam and Mojtabavi, Somayeh and Faramarzi, Mohammad Ali and Ghasemi, Fahimeh and Torabi, Mohammadreza and Tehrani, Maliheh Barazandeh and Sheibani, Vahid and Firoozpour, Loghman and Foroumadi, Alireza},
  title = {New coumarin–chalcone–triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validation},
  journal = {RSC Advances},
  year = {2025},
  volume = {15},
  number = {59},
  pages = {51136--51161},
  doi = {10.1039/d5ra07254a}
}
Kostenlos starten →